(Q34990961)

5 August 2017

1 reference

title

Adverse effects of anticancer agents that target the VEGF pathway (English)

1 reference

5 August 2017

Helen X Chen

1

1 reference

5 August 2017

Jessica N Cleck

series ordinal

2

1 reference

5 August 2017

language of work or name

English

0 references

publication date

7 July 2009

1 reference

Nature Reviews Clinical Oncology

5 August 2017

published in

1 reference

5 August 2017

volume

6

1 reference

5 August 2017

issue

8

1 reference

5 August 2017

page(s)

465-477

1 reference

Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.94

Vascular endothelial growth factor/vascular permeability factor produces nitric oxide-dependent hypotension. Evidence for a maintenance role in quiescent adult endothelium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.94

Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.94

Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.94

Angiogenic growth factors and hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.94

Hypertension, proteinuria, and antagonism of vascular endothelial growth factor signaling: clinical toxicity, therapeutic target, or novel biomarker?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.94

Capillary rarefaction and abnormal cardiovascular reactivity in hypertension

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.94

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.94

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.94

Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.94

Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.94

AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.94

Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.94

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.94

Sorafenib in advanced clear-cell renal-cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.94

Sorafenib in advanced hepatocellular carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.94

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.94

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.94

Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.94

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.94

A target-mediated model to describe the pharmacokinetics and hemodynamic effects of recombinant human vascular endothelial growth factor in humans

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.94

Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.94

Bevacizumab in metastatic colorectal cancer: a left intracardiac thrombotic event

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.94

A cardiac myocyte vascular endothelial growth factor paracrine pathway is required to maintain cardiac function

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.94

Hypertension-induced changes of platelet-derived growth factor receptor expression in rat aorta and heart

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.94

Growth-promoting effect of platelet-derived growth factor on rat cardiac myocytes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.94

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.94

Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-beta-d-arabinofuranosylcytosine, mitoxantrone, and bevacizumab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.94

Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.94

Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.94

Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.94

Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.94

The role of vascular endothelial growth factor (VEGF) in renal pathophysiology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.94

VEGF inhibition and renal thrombotic microangiopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.94

Interstitial nephritis secondary to bevacizumab treatment in metastatic leiomyosarcoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.94

Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.94

Proteinuria in a patient receiving anti-VEGF therapy for metastatic renal cell carcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.94

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.94

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.94

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.94

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.94

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.94

Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.94

Thrombotic microangiopathy and anti-VEGF agents

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.94

Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.94

Sunitinib induced hypertension, thrombotic microangiopathy and reversible posterior leukencephalopathy syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.94

Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.94

Unlocking the biological clues of lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.94

Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.94

Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.94

Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.94

Bevacizumab in the treatment of ovarian cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.94

Thrombospondin-1 suppresses wound healing and granulation tissue formation in the skin of transgenic mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.94

Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.94

Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.94

Clinical pharmacokinetics of bevacizumab in patients with solid tumors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.94

Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.94

Reversible posterior leukoencephalopathy syndrome: a misnomer reviewed

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.94

Neuroimaging in posterior reversible encephalopathy syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.94

Reversible posterior leukoencephalopathy syndrome and bevacizumab.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.94

Reversible posterior leukoencephalopathy syndrome after bevacizumab/FOLFIRI regimen for metastatic colon cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.94

Reversible posterior leukoencephalopathy syndrome induced by RAF kinase inhibitor BAY 43-9006

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.94

Reversible posterior leukoencephalopathy syndrome induced by sunitinib

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.94

VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.94

Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.94

VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.94

Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.94

Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.94

Cooperative group research efforts in lung cancer 2008: focus on advanced-stage non-small-cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.94

Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.94

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.94

Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.94

Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.94

Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: A retrospective analysis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.94

Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma

31 March 2020

1 reference

12 December 2020

A phase II pilot trial incorporating bevacizumab into dose-dense doxorubicin and cyclophosphamide followed by paclitaxel in patients with lymph node positive breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group

1 reference

12 December 2020

Reversible posterior leucoencephalopathy syndrome associated with anticancer drugs

1 reference

12 December 2020

VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells

1 reference

12 December 2020

Axitinib, a novel anti-angiogenic drug with promising activity in various solid tumors.

1 reference

12 December 2020

Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma.

1 reference

12 December 2020

Thrombotic microangiopathy associated with sunitinib, a VEGF inhibitor, in a patient with factor V Leiden mutation

1 reference

12 December 2020

Expression of the vascular endothelial growth factor (VEGF) receptor gene, KDR, in hematopoietic cells and inhibitory effect of VEGF on apoptotic cell death caused by ionizing radiation

1 reference

12 December 2020

10.1038/NRCLINONC.2009.94

Identifiers

DOI

1 reference

5 August 2017

1 reference